MedTrace Logo

Convalescent Plasma in the Treatment of COVID 19

NCT04343261 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-09-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  • COVID
  • Coronavirus

Interventions

BIOLOGICAL

Convalescent Plasma

treatment with 2 Units of convalescent plasma

Sponsors & Collaborators

  • Trinity Health Of New England

    lead OTHER

Principal Investigators

  • Latha Dulipsingh, MD · Saint Francis Hospital and Medical Centerr/Trinity Health Of New England

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-10
Primary Completion
2020-07-23
Completion
2020-08-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343261 on ClinicalTrials.gov